phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

According to researchers writing in The Lancet, we need a majority of Americans to have the confidence to get vaccinated for COVID-19 if we are going to be effective in moving the United States toward population-level control of viral spread. As Dr. Anthony Fauci has noted, “If you have a vaccine that is highly effective and not enough people get vaccinated, you’re not going to realize the full, important effect of having a vaccine.”

The good news is a growing majority of Americans are expressing COVID-19 vaccine readiness. The increase in confidence follows news about the first two COVID-19 vaccines confirmed with over 95% efficacy and the subsequent emergency use authorizations (EUA) granted by the U.S. Food and Drug Administration (FDA) for administration of the vaccines to patients.

Recent opinion research conducted by PhRMA[1], Gallup, Ipsos and others confirms this trend, with almost two-thirds of the U.S. public expressing willingness to get a vaccine if one were available to them today. Our most recent tracking survey, conducted with Morning Consult, shows 65% readiness for a vaccine, a 5-point increase from October. Gallup reports the same percentage and Ipsos shows an 8-point confidence boost of late, with 60% overall readiness. The PhRMA poll noted above also shows an 18-point increase in the number of Americans who say they will take a vaccine “right away” (45%, up from 27%).

Another big story in Gallup’s vaccine confidence numbers is the recent change by key subgroups. We have long seen significant differences in attitudes by gender, race, income, education and political party affiliation. Notably, the confidence gap has widened between Democrats (83%, up 8 points since December) and Republicans (45%, down 5 points), as well as between those with a 4-year college degree (77%, up 9 points) and those without (60%, down 1 point). The gender and race gaps, however, have closed over the past month to single digits (3 points and 5 points, respectively).

PhRMA_Catalyst_VaccineConfidence_BlogGraphics

In line with these numbers is a growing appreciation for the significant value COVID-19 vaccines provide. In our survey noted above, 72% of American voters agree (39% strongly) that vaccines are key to ending the pandemic, and the public widely recognizes that vaccines will not only help save lives (62% likely to happen after a vaccination becomes available) but also restore core aspects of our day-to-day living, including the re-opening of schools (62% likely), businesses (61% likely) and restaurants (58% likely). Recent public polling reinforces theses trend with the Axios-Ipsos Coronavirus Index showing new urgency in plans to be vaccinated, and Pew Research linking intent to be vaccinated to confidence in biopharmaceutical research and development (R&D).

As the biopharmaceutical industry continues to study new and ongoing vaccine candidates through clinical trials, continued education will be critical to recognizing the benefits of the vaccines. We also know there continues to be several important questions from the public about these vaccines. It is critical all health care stakeholders come together to share open, honest and transparent information to help instill confidence.

For more information about the COVID-19 vaccine development, visit https://phrma.org/coronavirus and https://www.cdc.gov/vaccines/covid-19/ or your local health authority’s webpage for information about the ongoing vaccination campaign.


[1] PhRMA Tracking Poll with Morning Consult, January 6-9 2021 (n=1992) registered voters; October 2-4, 2020 (n=1983 registered voters)

Mark Keida

Mark Keida, Ph.D. is Vice President in Public Affairs. He leads PhRMA’s message and polling team, supporting advocacy communications, paid media campaigns and earned media. Mark specializes in using data to guide narrative, campaign strategy and tactics.

Mark Keida

Why smart vaccine policy matters

August 3, 2026

New study: HPV vaccination helps prevent cervical cancer deaths

July 21, 2026

New research reinforces the importance of hepatitis B vaccination at birth

May 21, 2026

World Immunization Week: Putting preventable diseases in the past

April 24, 2026

Growing trend: Increased vaccine confidence

Vaccines

Coronavirus

Polling

Growing trend: Increased vaccine confidence

January 28, 2021

Growing trend: Increased vaccine confidence

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list